dpp 4 inhibitor and glp 1 agonist dpp-4_inhibitors [TUSOM Specific actions of GLP-1 receptor
Description
Glymour, M
Most available GLP-1 RAs are given as subcutaneous injections
in Bioenergetics and Professor at BYU
This could pave the way for innovative integrated treatment strategies to improve outcomes for patients affected by these intertwined conditions
The molecule and safety profile are identical
"If you lose less than 5 percent of your total weight within six months of starting the medication, you're most likely a non-responder and these types of medications will not work for you." In addition, severe side effects are possible
